Skip to main content

Blueprint Medicines Corporation (BPMC)

NASDAQ: BPMC · IEX Real-Time Price · USD
106.61 -2.86 (-2.61%)
Sep 24, 2021 4:00 PM EDT - Market closed
Market Cap6.24B
Revenue (ttm)828.10M
Net Income (ttm)340.15M
Shares Out58.41M
EPS (ttm)5.81
PE Ratio18.35
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume189,179
Open108.89
Previous Close109.47
Day's Range106.45 - 109.47
52-Week Range79.08 - 125.61
Beta0.71
AnalystsBuy
Price Target119.00 (+11.6%)
Est. Earnings DateOct 28, 2021

About BPMC

Blueprint Medicines Corporation, a precision therapy company, develops medicines for people with cancer and hematologic disorders, and multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy in the United States and Europe. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and fisogatinib, an orally available...

IndustryBiotechnology
IPO DateApr 30, 2015
CEOJeffrey Albers
Employees462
Stock ExchangeNASDAQ
Ticker SymbolBPMC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for BPMC stock is "Buy." The 12-month stock price forecast is 119.00, which is an increase of 11.62% from the latest price.

Price Target
$119.00
(11.62% upside)
Analyst Consensus: Buy

News

Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 4, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that, effective on August 1, 2021, the Compensation Committee of Blueprint Medicines' Board ...

1 month ago - PRNewsWire

Blueprint Medicines (BPMC) Misses on Q2 Earnings & Revenues

Blueprint Medicines (BPMC) misses estimates for revenues and earnings in the second quarter of 2021. Nevertheless, the company provides encouraging pipeline updates.

1 month ago - Zacks Investment Research

Blueprint Medicines (BPMC) Reports Q2 Loss, Lags Revenue Estimates

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -5.09% and -4.46%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Blueprint Medicines: Q2 Earnings Insights

Shares of Blueprint Medicines (NASDAQ:BPMC) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share were up 18.42% year over year to ($1.86), which were in line w...

1 month ago - Benzinga

Blueprint Medicines Reports Second Quarter 2021 Financial Results

CAMBRIDGE, Mass., July 29, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results and provided a business update for the second quarter ended June 30, 2021.

1 month ago - PRNewsWire

MD Anderson and Blueprint Medicines Announce Strategic Collaboration to Accelerate BLU-222 Development

HOUSTON and CAMBRIDGE, Mass., July 28, 2021 /PRNewswire/ -- The University of Texas MD Anderson Cancer Center and Blueprint Medicines Corporation (NASDAQ: BPMC) today announced a three-year strategic re...

1 month ago - PRNewsWire

Will Blueprint Medicines (BPMC) Report Negative Q2 Earnings? What You Should Know

Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Blueprint Medicines to Report Second Quarter 2021 Financial Results on Thursday, July 29, 2021

CAMBRIDGE, Mass., July 22, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), today announced that it will host a live conference call and webcast at 8:30 a.m.

2 months ago - PRNewsWire

Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 7, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy,...

2 months ago - PRNewsWire

3 Biotech Stocks Ready for Big Breakthroughs Like Biogen

This could be a breakthrough year for these three biotech stocks, resulting in massive gains for their stockholders similar to Biogen. The post 3 Biotech Stocks Ready for Big Breakthroughs Like Biogen a...

Other symbols:MYOVPRVB
3 months ago - InvestorPlace

Blueprint Medicines (BPMC) Gets FDA Nod for Ayvakyt in SM

The FDA approves Blueprint Medicines' (BPMC) lead drug, Ayvakit, for treating adult patients with advanced systemic mastocytosis.

3 months ago - Zacks Investment Research

FDA Approves Blueprint Medicines' AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis

CAMBRIDGE, Mass., June 16, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has approved AYVAKIT™ (avapritinib) for th...

3 months ago - PRNewsWire

Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 4, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that, effective on June 1, 2021, the Compensation Committee of Blueprint Medicines' Board of...

3 months ago - PRNewsWire

Blueprint Medicines to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., May 25, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced its participation in the following upcoming investor conferences.

4 months ago - PRNewsWire

Blueprint Medicines Presents ARROW Trial Data for GAVRETO® (pralsetinib) Highlighting Durable Clinical Activity in Pa...

CAMBRIDGE, Mass., May 19, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the presentation of updated Phase 1/2 ARROW trial data demonstrating durable clinical benefi...

4 months ago - PRNewsWire

8 Biotech Stocks With Major Catalysts on the Horizon

Biotech stocks frequently make big moves on a single trial result or FDA ruling. These 8 drugmakers are worth watching amid important events on deck this summer.

4 months ago - Kiplinger

Blueprint Medicines Appoints Percy Carter, MBA, Ph.D., as Chief Scientific Officer

CAMBRIDGE, Mass., May 17, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of Percy Carter, MBA, Ph.D.

4 months ago - PRNewsWire

Blueprint Medicines (BPMC) Q1 Earnings Beat, Revenues Lag

Blueprint Medicines' (BPMC) beat estimates for earnings in the first quarter of 2021 while revenues miss the same.

4 months ago - Zacks Investment Research

Recap: Blueprint Medicines Q1 Earnings

Shares of Blueprint Medicines (NASDAQ:BPMC) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share were up 18.48% over the past year to ($1.72), which beat the e...

4 months ago - Benzinga

Blueprint Medicines Reports First Quarter 2021 Financial Results

CAMBRIDGE, Mass., April 29, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the first quarter ended March 31, 2021.

4 months ago - PRNewsWire

Blueprint Medicines to Report First Quarter 2021 Financial Results on Thursday, April 29, 2021

CAMBRIDGE, Mass., April 22, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), today announced that it will host a live conference call and webcast at 8:30 a.m.

5 months ago - PRNewsWire

3 Magic Formula Health Care Stock Picks

If you want to enhance your likelihood to beat the market, one method is to select stocks that rank highly according to the "Magic Formula" criteria.

Other symbols:BDSIFLGT
5 months ago - GuruFocus

1 Cancer Stock to Buy and Hold for the Next Decade

Blueprint Medicines is setting itself up to become the leader in precision oncology.

5 months ago - The Motley Fool

Blueprint Medicines Data Highlight Clinical Leadership in Systemic Mastocytosis at AACR Annual Meeting 2021

CAMBRIDGE, Mass., April 11, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that multiple presentations across the company's leading systemic mastocytosis (SM) progra...

5 months ago - PRNewsWire

Blueprint Medicines Presents Preclinical Data Highlighting Broad Precision Therapy Research Pipeline at AACR Annual M...

CAMBRIDGE, Mass., April 10, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced data from multiple poster presentations highlighting the breadth of the company's precisio...

5 months ago - PRNewsWire